FDA Updates Mifepristone Labeling, Easing Access to Abortion Pill

    loading  Checking for direct PDF access through Ovid

Abstract

The Food and Drug Administration has approved new and updated labeling for the medication abortion drug mifepristone (Mifeprex, Danco Laboratories, New York City) to reflect the most current clinical practices and safety and efficacy data. The drug’s new label reduces the size of the initial dose and extends the window for taking it to 70 days since the first day of a woman’s last menstrual period.

Related Topics

    loading  Loading Related Articles